Duvakitug
Sponsors
Sanofi-Aventis Recherche & Developpement, Sanofi
Conditions
Crohn's DiseaseImmune system diseasesImmune system disseasesUlcerative Colitis
Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RecruitingNCT07184944
Start: 2026-01-22End: 2034-03-20Target: 671Updated: 2026-03-02
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingNCT07184996
Start: 2025-10-08End: 2028-05-09Target: 980Updated: 2026-03-30
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RecruitingNCT07184931
Start: 2025-10-01End: 2029-05-14Target: 980Updated: 2026-03-31
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingNCT07185009
Start: 2026-01-16End: 2033-04-28Target: 671Updated: 2026-04-03
A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis
Not yet recruitingCTIS2025-521038-27-00
Target: 89Updated: 2026-02-10
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis.
Not yet recruitingCTIS2025-521035-37-00
Target: 210Updated: 2026-02-10
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease
Not yet recruitingCTIS2025-521037-86-00
Target: 114Updated: 2026-02-25
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease
Not yet recruitingCTIS2025-521036-11-00
Target: 324Updated: 2026-02-25